JP2014512183A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014512183A5 JP2014512183A5 JP2014503979A JP2014503979A JP2014512183A5 JP 2014512183 A5 JP2014512183 A5 JP 2014512183A5 JP 2014503979 A JP2014503979 A JP 2014503979A JP 2014503979 A JP2014503979 A JP 2014503979A JP 2014512183 A5 JP2014512183 A5 JP 2014512183A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cell
- extracellular domain
- individual
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 20
- 230000003834 intracellular effect Effects 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 6
- 210000000987 immune system Anatomy 0.000 claims 6
- 206010005003 Bladder cancer Diseases 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 206010014733 Endometrial cancer Diseases 0.000 claims 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 3
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 3
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 3
- 206010038389 Renal cancer Diseases 0.000 claims 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims 3
- 208000000277 Splenic Neoplasms Diseases 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 3
- 206010057644 Testis cancer Diseases 0.000 claims 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 201000010175 gallbladder cancer Diseases 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 201000005787 hematologic cancer Diseases 0.000 claims 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 3
- 201000010982 kidney cancer Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 206010038038 rectal cancer Diseases 0.000 claims 3
- 201000001275 rectum cancer Diseases 0.000 claims 3
- 201000000849 skin cancer Diseases 0.000 claims 3
- 201000002471 spleen cancer Diseases 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- 201000003120 testicular cancer Diseases 0.000 claims 3
- 201000002510 thyroid cancer Diseases 0.000 claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 102000003816 Interleukin-13 Human genes 0.000 claims 2
- 108090000176 Interleukin-13 Proteins 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000003675 cytokine receptors Human genes 0.000 claims 2
- 108010057085 cytokine receptors Proteins 0.000 claims 2
- 210000002865 immune cell Anatomy 0.000 claims 2
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 1
- 101000972282 Homo sapiens Mucin-5AC Proteins 0.000 claims 1
- 101000972278 Homo sapiens Mucin-6 Proteins 0.000 claims 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 1
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims 1
- 101000880770 Homo sapiens Protein SSX2 Proteins 0.000 claims 1
- 102000003814 Interleukin-10 Human genes 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 102000003812 Interleukin-15 Human genes 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- -1 MAGEA Proteins 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 102100022496 Mucin-5AC Human genes 0.000 claims 1
- 102100022493 Mucin-6 Human genes 0.000 claims 1
- 108060006580 PRAME Proteins 0.000 claims 1
- 102000036673 PRAME Human genes 0.000 claims 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 1
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims 1
- 102100037686 Protein SSX2 Human genes 0.000 claims 1
- 108010002687 Survivin Proteins 0.000 claims 1
- 108010017842 Telomerase Proteins 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 210000004986 primary T-cell Anatomy 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161473457P | 2011-04-08 | 2011-04-08 | |
| US61/473,457 | 2011-04-08 | ||
| PCT/US2012/032322 WO2012138858A1 (en) | 2011-04-08 | 2012-04-05 | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016246100A Division JP6297129B2 (ja) | 2011-04-08 | 2016-12-20 | キメラサイトカイン受容体を用いて、腫瘍微小環境の影響を逆転する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014512183A JP2014512183A (ja) | 2014-05-22 |
| JP2014512183A5 true JP2014512183A5 (enExample) | 2015-04-09 |
| JP6066991B2 JP6066991B2 (ja) | 2017-01-25 |
Family
ID=46969548
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014503979A Expired - Fee Related JP6066991B2 (ja) | 2011-04-08 | 2012-04-05 | キメラサイトカイン受容体を用いて、腫瘍微小環境の影響を逆転する方法 |
| JP2016246100A Active JP6297129B2 (ja) | 2011-04-08 | 2016-12-20 | キメラサイトカイン受容体を用いて、腫瘍微小環境の影響を逆転する方法 |
| JP2018027460A Pending JP2018108091A (ja) | 2011-04-08 | 2018-02-20 | キメラサイトカイン受容体を用いて、腫瘍微小環境の影響を逆転する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016246100A Active JP6297129B2 (ja) | 2011-04-08 | 2016-12-20 | キメラサイトカイン受容体を用いて、腫瘍微小環境の影響を逆転する方法 |
| JP2018027460A Pending JP2018108091A (ja) | 2011-04-08 | 2018-02-20 | キメラサイトカイン受容体を用いて、腫瘍微小環境の影響を逆転する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10548921B2 (enExample) |
| EP (2) | EP3305890B1 (enExample) |
| JP (3) | JP6066991B2 (enExample) |
| CN (2) | CN107164330A (enExample) |
| AU (3) | AU2012240135B2 (enExample) |
| CA (1) | CA2832569A1 (enExample) |
| DK (1) | DK2694640T3 (enExample) |
| ES (1) | ES2649967T3 (enExample) |
| MX (2) | MX347656B (enExample) |
| NO (1) | NO2724929T3 (enExample) |
| NZ (3) | NZ723731A (enExample) |
| WO (1) | WO2012138858A1 (enExample) |
Families Citing this family (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9249423B2 (en) | 2007-02-02 | 2016-02-02 | Yale University | Method of de-differentiating and re-differentiating somatic cells using RNA |
| US10155038B2 (en) | 2007-02-02 | 2018-12-18 | Yale University | Cells prepared by transient transfection and methods of use thereof |
| US8956860B2 (en) | 2009-12-08 | 2015-02-17 | Juan F. Vera | Methods of cell culture for adoptive cell therapy |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| SG11201407819UA (en) * | 2012-06-11 | 2014-12-30 | Wolf Wilson Mfg Corp | Improved methods of cell culture for adoptive cell therapy |
| IN2015KN00329A (enExample) | 2012-08-09 | 2015-07-10 | Univ Leland Stanford Junior | |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| NZ750426A (en) * | 2013-02-06 | 2020-06-26 | Celgene Corp | Modified t lymphocytes having improved specificity |
| WO2014130635A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
| EP2958943B1 (en) | 2013-02-20 | 2019-09-11 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| CN105518018B (zh) | 2013-03-15 | 2020-04-03 | 细胞基因公司 | 修饰的t淋巴细胞 |
| US9745368B2 (en) | 2013-03-15 | 2017-08-29 | The Trustees Of The University Of Pennsylvania | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| CA2909701C (en) * | 2013-04-17 | 2022-12-06 | Baylor College Of Medicine | Immunosuppressive tgf-.beta. signal converter |
| CN105431456A (zh) * | 2013-06-14 | 2016-03-23 | 休斯敦系统大学 | 用修饰的嵌合抗原受体靶向肿瘤新生血管 |
| JP6585041B2 (ja) * | 2013-07-18 | 2019-10-02 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | 免疫細胞の能力を増強する方法 |
| CA3180148A1 (en) | 2013-09-24 | 2015-04-02 | Medicenna Therapeutics, Inc. | Interleukin-4 receptor-binding fusion proteins and uses thereof |
| SG11201604815RA (en) | 2013-12-19 | 2016-07-28 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
| US10287354B2 (en) | 2013-12-20 | 2019-05-14 | Novartis Ag | Regulatable chimeric antigen receptor |
| US11028143B2 (en) | 2014-01-21 | 2021-06-08 | Novartis Ag | Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules |
| LT3129470T (lt) | 2014-04-07 | 2021-07-12 | Novartis Ag | Vėžio gydymas naudojant anti-cd19 chimerinį antigeno receptorių |
| US20170158749A1 (en) * | 2014-04-23 | 2017-06-08 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) and methods for making and using the same |
| BR112017001183A2 (pt) | 2014-07-21 | 2017-11-28 | Novartis Ag | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado |
| SG11201700418VA (en) | 2014-07-21 | 2017-02-27 | Novartis Ag | Treatment of cancer using a cll-1 chimeric antigen receptor |
| WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| CN107109419B (zh) | 2014-07-21 | 2020-12-22 | 诺华股份有限公司 | 使用cd33嵌合抗原受体治疗癌症 |
| JP6631865B2 (ja) * | 2014-08-11 | 2020-01-15 | 日本化薬株式会社 | ＴＧＦβ阻害機能を持つキメラタンパク質 |
| ES2791248T3 (es) | 2014-08-19 | 2020-11-03 | Novartis Ag | Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer |
| EA201790624A1 (ru) | 2014-09-17 | 2017-08-31 | Новартис Аг | Нацеливание цитотоксических клеток с химерными рецепторами для адоптивной иммунотерапии |
| AU2015330898B2 (en) | 2014-10-08 | 2022-03-10 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
| MA41538A (fr) * | 2014-10-17 | 2017-12-26 | Baylor College Medicine | Cellules immunitaires bipartites et tripartites de signalisation |
| AU2015374296B2 (en) | 2014-12-29 | 2021-09-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| US11459390B2 (en) | 2015-01-16 | 2022-10-04 | Novartis Ag | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor |
| US10828353B2 (en) | 2015-01-31 | 2020-11-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for T cell delivery of therapeutic molecules |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| WO2016170541A1 (en) | 2015-04-21 | 2016-10-27 | Enlivex Therapeutics Ltd. | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
| WO2017141243A1 (en) | 2016-02-18 | 2017-08-24 | Enlivex Therapeutics Ltd. | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| KR20170117450A (ko) | 2015-02-18 | 2017-10-23 | 엔리벡스 테라퓨틱스 리미티드 | 암 치료를 위한 면역 요법 및 사이토카인 조절 요법의 조합 |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| CA2978186A1 (en) | 2015-03-05 | 2016-09-09 | Fred Hutchinson Cancer Research Center | Immunomodulatory fusion proteins and uses thereof |
| US20180072990A1 (en) * | 2015-03-20 | 2018-03-15 | Children's National Medical Center | Generating virus or other antigen-specific t cells from a naïve t cell population |
| SG11201708191XA (en) | 2015-04-08 | 2017-11-29 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell |
| EP4234685A3 (en) | 2015-04-17 | 2023-09-06 | Novartis AG | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| US12128069B2 (en) | 2015-04-23 | 2024-10-29 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| CN104910279B (zh) * | 2015-06-05 | 2019-02-22 | 重庆精准生物技术有限公司 | 靶向癌胚抗原的嵌合抗原受体、慢病毒表达载体及其制备方法和应用 |
| CN109476722A (zh) | 2015-07-21 | 2019-03-15 | 诺华股份有限公司 | 用于改善免疫细胞的功效和扩张的方法 |
| WO2017027392A1 (en) | 2015-08-07 | 2017-02-16 | Novartis Ag | Treatment of cancer using chimeric cd3 receptor proteins |
| GB201514875D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| CN108780084B (zh) | 2015-09-03 | 2022-07-22 | 诺华股份有限公司 | 预测细胞因子释放综合征的生物标志物 |
| GB201518816D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
| CN121294437A (zh) | 2015-12-04 | 2026-01-09 | 诺华股份有限公司 | 用于免疫肿瘤学的组合物和方法 |
| MA44140A (fr) | 2015-12-22 | 2021-05-19 | Dana Farber Cancer Inst Inc | Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse |
| WO2017165245A2 (en) * | 2016-03-19 | 2017-09-28 | F1 Oncology, Inc. | Methods and compositions for transducing lymphocytes and regulated expansion thereof |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
| SG11201901642XA (en) * | 2016-08-26 | 2019-03-28 | Baylor College Medicine | Constitutively active cytokine receptors for cell therapy |
| SG10201913823VA (en) | 2016-10-07 | 2020-03-30 | Novartis Ag | Chimeric antigen receptors for the treatment of cancer |
| WO2018075820A2 (en) | 2016-10-20 | 2018-04-26 | Celgene Corporation | Cereblon-based heterodimerizable chimeric antigen receptors |
| EP3541833B1 (en) | 2016-11-17 | 2024-01-24 | 2seventy bio, Inc. | Tgf beta signal convertor |
| WO2018140725A1 (en) | 2017-01-26 | 2018-08-02 | Novartis Ag | Cd28 compositions and methods for chimeric antigen receptor therapy |
| GB201702617D0 (en) * | 2017-02-17 | 2017-04-05 | Autolus Ltd | Receptor |
| BR112019018288A2 (pt) * | 2017-03-03 | 2020-03-31 | F1 Oncology, Inc. | Métodos e composições para transduzir e expandir linfócitos e regular a atividade dos mesmos |
| JP2020511136A (ja) | 2017-03-17 | 2020-04-16 | フレッド ハッチンソン キャンサー リサーチ センター | 免疫調節性融合タンパク質およびその使用 |
| AU2018237159A1 (en) | 2017-03-22 | 2019-09-05 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| EP4317422A3 (en) | 2017-04-13 | 2024-05-01 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| AU2018347796B2 (en) | 2017-10-10 | 2025-07-24 | Medicenna Therapeutics, Inc. | IL-4-fusion formulations for treatment of central nervous system (CNS) tumors |
| US11999802B2 (en) | 2017-10-18 | 2024-06-04 | Novartis Ag | Compositions and methods for selective protein degradation |
| CN109880803B (zh) * | 2017-12-06 | 2024-06-07 | 恺兴生命科技(上海)有限公司 | 嵌合蛋白、表达嵌合蛋白的免疫效应细胞及其应用 |
| SG11202007771VA (en) * | 2018-03-02 | 2020-09-29 | Allogene Therapeutics Inc | Inducible chimeric cytokine receptors |
| US10780120B2 (en) | 2018-03-06 | 2020-09-22 | The Trustees Of The University Of Pennsylvania | Prostate-specific membrane antigen cars and methods of use thereof |
| WO2019239213A2 (en) | 2018-06-01 | 2019-12-19 | Medicenna Therapeutics Inc. | Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof |
| CN118108857A (zh) * | 2018-06-01 | 2024-05-31 | 利兰斯坦福初级大学董事会 | 免疫细胞靶向性构建体 |
| EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| JP7438988B2 (ja) | 2018-06-13 | 2024-02-27 | ノバルティス アーゲー | Ｂｃｍａキメラ抗原受容体及びその使用 |
| CN110615843B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种包含第三信号受体的嵌合抗原受体及其应用 |
| US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| AU2019359890B2 (en) | 2018-10-17 | 2024-10-24 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| US20200147137A1 (en) * | 2018-11-08 | 2020-05-14 | WUGEN, Inc. | Compositions and methods for treatment of cancer |
| CN116479022A (zh) * | 2018-12-12 | 2023-07-25 | 中南大学 | 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用 |
| CA3129865A1 (en) | 2019-03-01 | 2020-09-10 | Allogene Therapeutics, Inc. | Constitutively active chimeric cytokine receptors |
| KR20210136042A (ko) * | 2019-03-01 | 2021-11-16 | 알로젠 테라퓨틱스 인코포레이티드 | Pd-1 엑토도메인을 보유하는 키메라 사이토카인 수용체 |
| CN115151275A (zh) | 2019-08-30 | 2022-10-04 | 耶鲁大学 | 用于向细胞递送核酸的组合物和方法 |
| KR102275668B1 (ko) * | 2019-09-26 | 2021-07-12 | 충북대학교 산학협력단 | 면역신호의 변환이 가능한 키메릭 사이토카인 수용체, 이를 발현하는 면역세포 및 이의 항암 용도 |
| JP2023503161A (ja) | 2019-11-26 | 2023-01-26 | ノバルティス アーゲー | Ｃｄ１９及びｃｄ２２キメラ抗原受容体及びその使用 |
| JP7714545B2 (ja) | 2019-11-26 | 2025-07-29 | ノバルティス アーゲー | キメラ抗原受容体及びその使用 |
| BR112022016657A2 (pt) | 2020-02-24 | 2022-12-20 | Allogene Therapeutics Inc | Células car-t bcma com atividades melhoradas |
| WO2021170666A1 (en) | 2020-02-25 | 2021-09-02 | Quell Therapeutics Limited | Chimeric receptors for use in engineered cells |
| IL301014A (en) | 2020-08-31 | 2023-05-01 | Univ Yale | Compositions and methods for delivery of nucleic acids to cells |
| JP2025513801A (ja) | 2022-04-08 | 2025-04-30 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 多部位受容体及びシグナル伝達複合体 |
| JP2025540052A (ja) | 2022-12-01 | 2025-12-11 | イェール ユニバーシティー | 細胞内ペイロード送達用刺激応答性トレースレス操作プラットフォーム |
| WO2024140501A1 (zh) * | 2022-12-27 | 2024-07-04 | 广州瑞风生物科技有限公司 | 一种融合蛋白及其应用 |
| AU2024212695A1 (en) | 2023-01-23 | 2025-08-14 | Medizinische Hochschule Hannover | Anti-entpd3 chimeric antigen receptor |
| EP4403580A1 (en) | 2023-01-23 | 2024-07-24 | Medizinische Hochschule Hannover | Anti-entpd3 chimeric antigen receptor |
| IL322333A (en) | 2023-02-07 | 2025-09-01 | Quell Therapeutics Ltd | Culture method for TREG cells |
| WO2024175805A1 (en) | 2023-02-24 | 2024-08-29 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| EP4420676A1 (en) | 2023-02-24 | 2024-08-28 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| CN116284449B (zh) * | 2023-02-27 | 2024-11-19 | 深圳市先康达生命科学有限公司 | 增强型TGF-βR嵌合受体及其应用 |
| AU2024233625A1 (en) | 2023-03-03 | 2025-09-18 | Arsenal Biosciences, Inc. | Systems targeting psma and ca9 |
| WO2024194605A1 (en) | 2023-03-17 | 2024-09-26 | Quell Therapeutics Limited | Treg therapy |
| WO2024194355A1 (en) | 2023-03-20 | 2024-09-26 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| EP4434539A1 (en) | 2023-03-20 | 2024-09-25 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024193687A1 (en) * | 2023-03-23 | 2024-09-26 | Nanjing Legend Biotech Co., Ltd. | Inverted cytokine receptors and methods of use thereof |
| AU2024243972A1 (en) * | 2023-04-06 | 2025-10-23 | Memorial Hospital For Cancer And Allied Diseases | Il-10 receptor antibodies and methods of use thereof |
| CN116496417B (zh) * | 2023-06-27 | 2023-10-10 | 北京市肿瘤防治研究所 | 含有膜型il7的融合蛋白及t细胞 |
| WO2025016399A1 (en) * | 2023-07-17 | 2025-01-23 | Nanjing Legend Biotech Co., Ltd. | Fusion proteins and methods of use thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994022914A1 (en) * | 1993-04-06 | 1994-10-13 | Fred Hutchinson Cancer Research Center | Chimeric cytokine receptors in lymphocytes |
| JP2002516562A (ja) | 1996-03-04 | 2002-06-04 | ターゲティッド ジェネティックス コーポレイション | Ｔリンパ球のインビトロ増殖のための改変された迅速な拡大方法（「改変ｒｅｍ」） |
| US6130087A (en) | 1996-10-07 | 2000-10-10 | Fordham University | Methods for generating cytotoxic T cells in vitro |
| US20020114812A1 (en) | 2001-01-12 | 2002-08-22 | Riichiro Abe | Methods and compositions for modulating regulation of the cytotoxic lymphocyte response by macrophage migration inhibitory factor |
| JP4448282B2 (ja) * | 2001-04-30 | 2010-04-07 | シティ・オブ・ホープ | ヒト癌を処置するのに有用なキメライムノレセプター |
| US20090257994A1 (en) * | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US7235392B2 (en) | 2001-12-07 | 2007-06-26 | The Ohio State University Research Foundation | Apoptotic EBV-transformed lymphocytes, a therapeutic agent for post-transplant lymphoproliferative disorder |
| WO2004019953A1 (en) * | 2002-08-28 | 2004-03-11 | Hollis-Eden Pharmaceuticals, Inc. | Therapeutic treatment methods |
| WO2004042025A2 (en) | 2002-11-01 | 2004-05-21 | Cell Genesys, Inc. | Cell-specific adenovirus vector comprising ebv-specific promoter |
| JP2004315381A (ja) * | 2003-04-11 | 2004-11-11 | Japan Science & Technology Agency | ナチュラルキラーＴ細胞のインターロイキン１８による刺激を利用した免疫疾患治療薬剤および治療キット、並びにＩｇＥ産生の制御方法 |
| US7435592B2 (en) * | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
| DE602004031341D1 (de) * | 2003-07-21 | 2011-03-24 | Transgene Sa | Multifunktionelle cytokine |
| US20070071759A1 (en) * | 2005-06-29 | 2007-03-29 | University Of Miami | Antibody-immune cell ligand fusion protein for cancer therapy |
| GB0917090D0 (en) | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
| WO2013123061A1 (en) | 2012-02-13 | 2013-08-22 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| CA2934436A1 (en) | 2013-12-20 | 2015-06-25 | Cellectis | Method of engineering multi-input signal sensitive t cell for immunotherapy |
-
2012
- 2012-04-05 CN CN201710136120.8A patent/CN107164330A/zh active Pending
- 2012-04-05 CN CN201280024856.1A patent/CN103582699B/zh active Active
- 2012-04-05 EP EP17190649.8A patent/EP3305890B1/en active Active
- 2012-04-05 EP EP12767723.5A patent/EP2694640B1/en active Active
- 2012-04-05 WO PCT/US2012/032322 patent/WO2012138858A1/en not_active Ceased
- 2012-04-05 DK DK12767723.5T patent/DK2694640T3/da active
- 2012-04-05 JP JP2014503979A patent/JP6066991B2/ja not_active Expired - Fee Related
- 2012-04-05 NZ NZ723731A patent/NZ723731A/en not_active IP Right Cessation
- 2012-04-05 US US14/110,582 patent/US10548921B2/en active Active
- 2012-04-05 MX MX2013011742A patent/MX347656B/es active IP Right Grant
- 2012-04-05 ES ES12767723.5T patent/ES2649967T3/es active Active
- 2012-04-05 CA CA2832569A patent/CA2832569A1/en active Pending
- 2012-04-05 NZ NZ710810A patent/NZ710810A/en not_active IP Right Cessation
- 2012-04-05 MX MX2017005885A patent/MX380522B/es unknown
- 2012-04-05 AU AU2012240135A patent/AU2012240135B2/en not_active Ceased
- 2012-04-05 NZ NZ616405A patent/NZ616405A/en not_active IP Right Cessation
-
2013
- 2013-08-08 NO NO13003957A patent/NO2724929T3/no unknown
-
2016
- 2016-11-01 AU AU2016253549A patent/AU2016253549B2/en not_active Ceased
- 2016-12-20 JP JP2016246100A patent/JP6297129B2/ja active Active
-
2018
- 2018-02-20 JP JP2018027460A patent/JP2018108091A/ja active Pending
- 2018-07-04 AU AU2018204850A patent/AU2018204850B2/en not_active Ceased
-
2020
- 2020-01-15 US US16/743,968 patent/US11717538B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014512183A5 (enExample) | ||
| JP7527049B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| JP6888225B2 (ja) | 改善された特異性を有する改変型ｔリンパ球 | |
| Houot et al. | T-cell–based immunotherapy: adoptive cell transfer and checkpoint inhibition | |
| Kershaw et al. | Gene-engineered T cells for cancer therapy | |
| Gill et al. | Chimeric antigen receptor T cell therapy: 25 years in the making | |
| Dar et al. | Insights into the relationship between toll like receptors and gamma delta T cell responses | |
| JP2017513470A5 (enExample) | ||
| JP2018522567A5 (enExample) | ||
| ES2837628T3 (es) | Linfocitos T modificados | |
| Chung et al. | A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy | |
| JP2016513458A5 (enExample) | ||
| RU2016143388A (ru) | Экспрессия трансгенов, регулируемая лекарственным средством | |
| Zhang et al. | Genetic engineering with T cell receptors | |
| DeRenzo et al. | The Landscape of CAR T cells beyond ALL for Pediatric Solid Tumors | |
| WO2019210293A1 (en) | Car t cells with one or more interleukins | |
| US20250163128A1 (en) | T cell expressing an fc gamma receptor and methods of use thereof | |
| JP2018531016A5 (enExample) | ||
| Pedrazzoli et al. | Is adoptive T-cell therapy for solid tumors coming of age? | |
| Hanagiri et al. | Retracted: Antitumor activity of human γδ T cells transducted with CD 8 and with T‐cell receptors of tumor‐specific cytotoxic T lymphocytes | |
| US20250066447A1 (en) | Engineered tcr complex and methods of using game | |
| EP4130028A1 (en) | Engineered tcr complex and methods of using same | |
| JPWO2020163634A5 (enExample) | ||
| JP2018522594A5 (enExample) | ||
| Shamalov et al. | Adoptive T-cell immunotherapy: perfecting self-defenses |